ALB and atrial fibrillation: Epidemiological evidence reveals progressive cardiovascular risk escalation with declining albumin levels, particularly manifesting as a 23% increased AF incidence per 5 g/L decrement (95% CI 1.12–1.35) across cardiometabolic disease cohorts.